AVITA Medical, Inc. (RCEL)
Market Cap | 343.52M |
Revenue (ttm) | 25.11M |
Net Income (ttm) | -17.79M |
Shares Out | 25.30M |
EPS (ttm) | -0.71 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 86,418 |
Open | 13.52 |
Previous Close | 13.53 |
Day's Range | 13.51 - 13.83 |
52-Week Range | 4.41 - 14.75 |
Beta | 0.97 |
Analysts | Buy |
Price Target | 19.28 (+41.97%) |
Earnings Date | Feb 23, 2023 |
About RCEL
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professional... [Read more]
Financial Performance
In 2022, AVITA Medical's revenue was 37.64 million, an increase of 8.73% compared to the previous year's 34.62 million. Losses were -26.67 million, 6.06% more than in 2021.
Financial numbers in AUD Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for RCEL stock is "Buy." The 12-month stock price forecast is $19.28, which is an increase of 41.97% from the latest price.
News

AVITA Medical Appoints New Non-Executive Member to the Board of Directors
VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

What Makes Avita Medical Inc. (RCEL) a Good Fit for 'Trend Investing'
Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it t...

How Much Upside is Left in Avita Medical Inc. (RCEL)? Wall Street Analysts Think 27.42%
The mean of analysts' price targets for Avita Medical Inc. (RCEL) points to a 27.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo...

AVITA Medical to Present at the TD Cowen 43rd Annual Health Care Conference
VALENCIA, Calif. and MELBOURNE, Australia, March 02, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

Here's Why 'Trend' Investors Would Love Betting on Avita Medical Inc. (RCEL)
Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it t...

AVITA Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and c...

AVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial Guidance
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

Avita Medical Inc. (RCEL) Stock Jumps 6.2%: Will It Continue to Soar?
Avita Medical Inc. (RCEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d...

AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical” or the “Company”), a regenerative medicine company leading th...

AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo
VALENCIA, Calif., and MELBOURNE, Australia, Dec. 19, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders
VALENCIA, Calif. and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commerc...

AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair
VALENCIA, Calif., and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference
VALENCIA, Calif., and MELBOURNE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

AVITA Medical® to Host Investor Webinar Briefing
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

Wall Street Analysts See a 127% Upside in Avita Medical Inc. (RCEL): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 127.1% in Avita Medical Inc. (RCEL). While the effectiveness of this highly sought-after metric is questionable...

AVITA Medical Reports Third Quarter 2022 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and c...

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

AVITA Medical to Announce Third Quarter 2022 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...

AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer
VALENCIA, Calif. and MELBOURNE, Australia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

Investor Webinar Briefing (RCEL, AVH)
Valencia, California and Melbourne, Australia--(Newsfile Corp. - September 19, 2022) - AVITA Medical, Inc. (NASDAQ: RCEL) (ASX: AVH), a regenerative medicine company leading the development and commer...

Investor Webinar Briefing
VALENCIA, Calif. and MELBOURNE, Australia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...

AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System
VALENCIA, Calif. and MELBOURNE, Australia, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commer...

RECELL® System Data to be Presented at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting
Two presentations will highlight data utilizing the RECELL platform for repigmentation Two presentations will highlight data utilizing the RECELL platform for repigmentation

AVITA Medical Reports Second Quarter 2022 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and commer...